NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis $0.01 +0.01 (+1,287.50%) As of 06/16/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Virpax Pharmaceuticals Stock (NASDAQ:VRPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virpax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0111▼$0.011150-Day Range N/A52-Week Range$0.00▼$0.48Volume283 shsAverage Volume1,209 shsMarket Capitalization$13.79 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and manufacturing of vaccines and injectable therapeutics. Headquartered in Fort Lauderdale, Florida, the company leverages proprietary formulation and drug‐delivery platforms to enhance the stability, bioavailability and tolerability of its product candidates. Virpax’s integrated model spans early-stage discovery through cGMP manufacturing, enabling seamless progression from laboratory proof‐of‐concept to large-scale production. Virpax’s pipeline encompasses a range of vaccine candidates targeting diseases such as rabies, herpes zoster and other infectious threats. Its proprietary adjuvant systems and lipid-based delivery technologies are designed to optimize immune responses while minimizing reactogenicity. In addition to vaccines, the company develops specialty injectable formulations for small molecules and biologics, addressing challenges related to solubility, absorption and patient compliance. Virpax advances its programs through collaborations with academic institutions, government agencies and contract development organizations, reinforcing its focus on both endemic and emerging health risks. Since its founding, Virpax has invested in scalable U.S. manufacturing capabilities that adhere to current Good Manufacturing Practices. The company’s strategic emphasis on vaccine innovation and formulation expertise positions it to serve domestic and selected international markets. As Virpax progresses its pipeline through preclinical and clinical milestones, its leadership continues to pursue partnerships and licensing opportunities to accelerate the development and commercialization of its vaccine and injectable portfolios.AI Generated. May Contain Errors. Read More Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRPX Stock News HeadlinesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Virpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comSee More Headlines VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed this year? Virpax Pharmaceuticals' stock was trading at $0.0111 at the beginning of the year. Since then, VRPX stock has increased by 0.0% and is now trading at $0.0111. When did Virpax Pharmaceuticals' stock split? Virpax Pharmaceuticals's stock reverse split on the morning of Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $20 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virpax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS). Company Calendar Today6/16/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRPX CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($123.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,554.34% Return on Assets-338.29% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.01Miscellaneous Outstanding Shares1,242,000Free Float4,707,000Market Cap$13.79 thousand OptionableNot Optionable Beta2.28 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VRPX) was last updated on 6/17/2026 by MarketBeat.com Staff. From Our PartnersIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
